Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Müller, Iris I ^a   Müller, Karin A L ^a   Schönleber, Heiko ^a   Karathanos, Athanasios ^a   Schneider, Martina ^a   Jorbenadze, Rezo ^a   Bigalke, Boris ^a   Gawaz, Meinrad ^a   Geisler, Tobias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TROPONIN I;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE;

EID: 84872754527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038376     Document Type: Article

References (20)

1. Ross R, (1999) Atherosclerosis- an inflammatory disease. N Engl J Med 340 (2): 115-26.
2. Geisler T, Bhatt DL, (2004) The role of inflammation in atherothrombosis: current and future strategies of medical treatment. Review. Med Sci Monit 10 (12): RA308-16.
3. Gawaz M, Langer H, May AE, (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115 (12): 3378-84.
4. May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, et al. (2002) Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106 (16): 2111-7.
5. Gresele P, Falcinelli E, Loffredo F, Cimmino G, Corazzi T, et al. (2011) Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J. 32 (3): 316-25.
6. van der Wal AC, Becker AE, van der Loos CM, Das PK, (1994) Site of intimal rupture of erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36-44.
7. Roger T, David J, Glauser MP, Calandra T, (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414 (6866): 920-4.
8. Calandra T, Roger T, (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3 (10): 791-800.
9. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J, (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Review. Microbes Infect 4 (4): 449-60.
10. Schmeisser A, Marquetant R, Illmer T, Graffy C, Garlichs CD, et al. (2005) The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis 178 (1): 83-94.
11. Zernecke A, Shagdarsuren E, Weber C, (2008) Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28 (11): 1897-908.
12. Soehnlein O, Lindbom L, Weber C, (2009) Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood 114 (21): 4613-23.
13. Calandra T, Roger T, (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800.
14. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
15. Schober A, Bernhagen J, Weber C, (2008) Chemokine-like functions of MIF in atherosclerosis. J Mol Med 86: 761-770.
16. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, et al. (2000) De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87: 1202-1208.
17. Yang LX, Guo RW, Qi F, Miao GH, Wang XM, et al. (2008) Association between plasma macrophage migration inhibitory factor concentration and coronary artery lesion severity. Zhonghua Xin Xue Guan Bing Za Zhi 36 (10): 912-5.
18. Müller K, Aichele S, Herkommer M, Bigalke B, Stellos K, et al. (2010) Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 213 (1): 256-62.
19. Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, et al. (2010) The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. J Invasive Cardiol 22 (1): 2-6.
20. Ouertatani-Sakouhi H, El-Turk F, Fauvet B, Cho MK, Pinar Karpinar D, et al. (2010) Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J Biol Chem 285 (34): 26581-98.